Tobramycin pharmacokinetics in morbidly obese patients. 1979

R A Blouin, and H J Mann, and W O Griffen, and L A Bauer, and K E Record

Tobramycin kinetics were examined in 9 morbidly obese women following a single intravenous (120 mg) bolus. After the injection, serum elimination conformed to a 2-compartment open model with alpha and beta t1/2s of 0.285 and 2.1 hr. The volume of distribution (Varea) was determined to be 0.44 1/kg ideal body weight (IBW) and 0.20 1/kg total body weight (TBW). To normalize Varea to 0.26 1/kg, 58% of the patients' adipose weight (TBW -- IBW) must also be taken into account.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D014031 Tobramycin An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species. Nebramycin Factor 6,Brulamycin,Nebcin,Nebicin,Obracin,Tobracin,Tobramycin Sulfate,Sulfate, Tobramycin

Related Publications

R A Blouin, and H J Mann, and W O Griffen, and L A Bauer, and K E Record
April 1980, American journal of hospital pharmacy,
R A Blouin, and H J Mann, and W O Griffen, and L A Bauer, and K E Record
November 2011, Clinical pharmacokinetics,
R A Blouin, and H J Mann, and W O Griffen, and L A Bauer, and K E Record
October 2011, European journal of clinical pharmacology,
R A Blouin, and H J Mann, and W O Griffen, and L A Bauer, and K E Record
January 1985, Clinical pharmacy,
R A Blouin, and H J Mann, and W O Griffen, and L A Bauer, and K E Record
November 1990, DICP : the annals of pharmacotherapy,
R A Blouin, and H J Mann, and W O Griffen, and L A Bauer, and K E Record
March 2017, Journal of clinical pharmacology,
R A Blouin, and H J Mann, and W O Griffen, and L A Bauer, and K E Record
March 2017, Antimicrobial agents and chemotherapy,
R A Blouin, and H J Mann, and W O Griffen, and L A Bauer, and K E Record
August 2015, The Journal of antimicrobial chemotherapy,
R A Blouin, and H J Mann, and W O Griffen, and L A Bauer, and K E Record
October 2011, The Journal of antimicrobial chemotherapy,
R A Blouin, and H J Mann, and W O Griffen, and L A Bauer, and K E Record
October 2015, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!